TenderlineUK
Procurement Intelligence
Official OCDS

ABBVIE LTD — UK Government Contract Awards

Maidenhead, UKJ11, GB
Procurements won
44
Awards
63
Distinct buyers
12
Awarded GBP value
£0
Published organisation identifiers
GB-COH:08004972GB-FTS-107065GB-FTS-107960GB-FTS-122619GB-FTS-142402GB-FTS-151675GB-FTS-155726GB-FTS-156007GB-FTS-23253GB-FTS-23570GB-FTS-4176GB-FTS-46352GB-FTS-5313GB-FTS-56730GB-FTS-58894GB-FTS-61094GB-FTS-76282GB-FTS-77524GB-FTS-77553GB-FTS-8709GB-FTS-90125GB-PPON:PHRQ-1133-WGCH
Recent awards
Award / procedureBuyerAwardedAward value
Lot 1 - CM/PHR/25/5731/01 – NHS Branded Medicines Tranche B for London & South of England.NHS England1 Jun 2026, 00:00 BST£813,863,584
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026NHS EnglandNot publishedNot published
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics ServiceNot publishedNot published
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics ServiceNot publishedNot published
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics ServiceNot publishedNot published
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Regional Business Services Organisation, Procurement and Logistics ServiceNot publishedNot published
NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiativesNHS EnglandNot publishedNot published
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025NHS EnglandNot publishedNot published
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025NHS EnglandNot publishedNot published
Proprietary DrugseTenderwalesNot publishedNot published